EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease

Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis Sk Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim und 1 weitere

Clinical and Molecular Hepatology · 01.07.2025 · 31 (3) · 796-809

DOI: 10.3350/cmh.2024.0822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2025. Verfasst von Tung-Hung Su und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, Fatty Liver. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Taiwan University Hospital, NIDDK NIH HHS, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: There are no hepatocellular carcinoma (HCC) surveillance recommendations for non-viral chronic liver diseases (CLD), such as metabolic dysfunction-associated steatotic liver disease (MASLD). We explored the Steatosis-Associated Fibrosis Estimator (SAFE) score to predict HCC in MASLD and other CLD etiologies.

Methods

Patients with various CLDs were included from medical centers in Taiwan. The SAFE score, consisting of age, body mass index, diabetes, and laboratory data, was calculated at baseline, and patients were traced for new development of HCC. The predictability of the SAFE score for HCC was analyzed using the sub-distribution hazard model with adjustments for competing risks.

Results

Among 12,963 CLD patients with a median follow-up of 4 years, 258 developed HCC. The SAFE score classifies 1-, 3-, and 5-year HCC risk regardless of CLD etiologies. High (≥100) and intermediate (0–100) SAFE scores increased 11 and 2 folds HCC risks compared to low (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisFatty LiverHepatitis, Viral, HumanHumansMaleFemaleMiddle AgedAgedRisk FactorsTaiwanProportional Hazards ModelsAdultBody Mass IndexFollow-Up Studies

Stichwörter der Autor:innen

Alcohol-related liver diseaseCirrhosisHepatitis BLiver cancerNon-alcoholic fatty liver disease

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Ph.D. Program in Translational Medicine; Institute of Biomedical Sciences; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.

Förderung

  • National Taiwan University Hospital
  • NIDDK NIH HHS
  • Gilead Sciences
  • National Science and Technology Council, Taiwan
  • Liver Disease Prevention and Treatment Research Foundation
  • National Taiwan University
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Su, T. H., Yang, S. S., Lee, M. H., Kao, W. Y., Huang, S. C., Chen, F. F., Poon, F. S., Tsai, L. W., Chen, Y. T., Lin, C., Wang, W., Kim, W. R., & Kao, J. H. (2025). High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology, 31(3), 796-809. https://doi.org/10.3350/cmh.2024.0822

Vancouver

Su TH, Yang SS, Lee MH, Kao WY, Huang SC, Chen FF, et al. High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 2025;31(3):796-809. doi:10.3350/cmh.2024.0822

BibTeX
@article{Su2025,
  author = {Su, Tung-Hung and Yang, Sheng-Shun and Lee, Mei-Hsuan and Kao, Wei-Yu and Huang, Shang-Chin and Chen, Fen-Fang and Poon, Francis Sk and Tsai, Lung-Wen and Chen, Yi-Ting and Lin, Che and Wang, Weichung and Kim, W Ray and Kao, Jia-Horng},
  title = {High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  volume = {31},
  number = {3},
  pages = {796--809},
  doi = {10.3350/cmh.2024.0822}
}
Kostenlos starten →